Clinical trial successes, especially those meeting primary endpoints, are critical milestones for biotech companies. The positive outcome of the MANIFEST-2 study is likely to be viewed favorably by investors and could lead to an increase in MorphoSys' stock price in the short term. The data indicating significant improvements in both spleen volume reduction and symptom reduction for intermediate-risk patients enhances the drug's profile, potentially increasing its marketability and future revenue prospects.